Drugs / GLPG3970
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04907149 | Jun → Jul 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04708184 | Jan → Feb 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04720183 | Jan → Apr 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04700267 | Dec 2020 → Oct 2021 | systemic lupus erythematosus | Lakefront Biotherapeutics NV | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04106297 | Sep 2019 → Mar 2021 | psoriasis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 23 trials · 3 missed | ||||||
| Phase 2 | NCT04700280 | Jan → Oct 2021 | Sjogren syndrome | Lakefront Biotherapeutics NV | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT04577781 | Oct 2020 → Mar 2021 | rheumatoid arthritis | Lakefront Biotherapeutics NV | Completed | Missed primary |
| Phase 2 | NCT04577794 | Oct 2020 → May 2021 | ulcerative colitis | Lakefront Biotherapeutics NV | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG3970 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04577794 ↗ |
| Route | Oral | “GLPG3970 for oral administration” NCT04106297 ↗ |